Video

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Author(s):

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Both escalation and de-escaltation will play a role in the future of breast cancer. There are ongoing trials investigating the de-escalation of radiotherapy, explains Houber.

However, there will also need to be scenarios of escalation in patients with triple-negative breast cancer. What is currently being investigated is adding to cisplatin-based chemotherapy to increase the efficacy.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD